is a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.
01/23/2012 - Company Blog
ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients
01/10/2012 - Chairman's Blog
Clinical Trials, Results, and Timing
Jan. 9 - Jan. 11, 2012
Biotech Showcase 2012
Click here to access the ACT presentation (PDF)
Oct. 3 - Oct. 5, 2011
World Stem Cell Summit, Pasadena, Calif.
Sep. 19 - Sep. 21, 2011
Phacilitate Cell & Gene Therapy Forum Asia 2011
ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients
Regenerative Medicine Track at Biotech Showcase 2012
Click here to access the ACT presentation (PDF)
Presentation at Stem Cells USA & Regenerative Medicine Congress 2011 in Boston, September 14, 2011
Click here for our company profile (PDF)
Eye Study Is a Small but Crucial Advance for Stem-Cell Therapy - Technology Review
Blindness Eased by Historic Stem Cell Treatment - New Scientist